{"id":"br1400-b","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Limited public information is available regarding the specific molecular mechanism of BR1400-B. As a phase 2 candidate from Boryung Pharmaceutical, the drug is still in clinical development with mechanism details potentially proprietary or not yet fully disclosed in accessible literature.","oneSentence":"BR1400-B is an investigational therapeutic in phase 2 development by Boryung Pharmaceutical with an undisclosed or proprietary mechanism of action.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T03:58:47.356Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT07373613","phase":"PHASE2","title":"A Study of BR1400-1, BR1400-2, BR1400-3, BR1400-4, and BR1400-5 in Patients With Essential Hypertension","status":"NOT_YET_RECRUITING","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2026-03-01","conditions":"Essential Hypertension","enrollment":330}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Placebo"],"phase":"phase_2","status":"active","brandName":"BR1400-B","genericName":"BR1400-B","companyName":"Boryung Pharmaceutical Co., Ltd","companyId":"boryung-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}